uncertainty, considering of benefit and was the case here. but it was very clear as you mentioned earlier evidence on the biomarker on impact of the drug and completely removing these amyloid plaques for the brain, so that are thought to cause of the disease in the real question was if you get rid of this amyloid protein for the brain, will people slow their rate of decline and there was clearly some suggestion in the data that this would happen, so the fda could have rejected the drug company could have rejected the drug company could approved it without any restrictions, they took a middle ground in the face of this uncertainty and gave it what is called an x accelerated approval which means that based on the biomarker evidence of the removal of the plaques by this amyloid scan, and whatever clinical evidence they have they have approved the drug condition requiring the company to do another study which is called a